Clinical Trials Search | Clareo Health

Showing 1-1 of 1 trials

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

NCT06494150

This single arm phase II study proposes to evaluate the efficacy and safety of nab-sirolimus + endocrine therapy (Fulvestrant) in patients with recurrent low grade serous ovarian cancer (LGSOC).

Low Grade Ovarian Serous Adenocarcinoma

University of Oklahoma37 participantsStarted Dec 2024

Oklahoma City, Oklahoma, United States

Data from ClinicalTrials.govTerms

Filters

Filters

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)